Zobrazeno 1 - 10
of 250
pro vyhledávání: '"D J, Sumner"'
Autor:
D. J. Sumner
Publikováno v:
Journal of Hypertension. 10:3-8
Publikováno v:
Journal of Cardiovascular Pharmacology. 16:191-196
Thirty-seven essential hypertensives received placebo for 3 weeks followed by nifedipine retard (n = 14) or enalapril (n = 13) or doxazosin (n = 10) as monotherapy for 6 weeks and attended study days to evaluate the effects of placebo, first dose, an
Autor:
A T, Elliott, D J, Sumner
Publikováno v:
Nuclear medicine communications. 12(1)
Autor:
W S Watson, D J Sumner
Publikováno v:
The British Journal of Radiology. 70:1314-1314
Publikováno v:
Journal of Hypertension. 12:1327
Publikováno v:
British Journal of Clinical Pharmacology. 26:715-720
1. The relationship between fall in systolic blood pressure and initial systolic blood pressure has been investigated in 255 mixed normotensive and hypertensive subjects given placebo or one of five types of antihypertensive drug (ACE inhibitors, cal
Publikováno v:
Scottish Medical Journal. 20:329-332
Peroheme 40, a chemical test for occult blood in faeces, has been assessed by. comparing it with results obtained using 51Cr labelled red cells. The study was carried out in two parts. Initially testing was carried out on 75 stool samples from 20 pat
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 14:77-85
SUMMARY 1. The effects of the calcium antagonists verapamil and nifedipine on mean arterial blood pressure, heart rate and pressor responses to a range of α-adrenoceptor agonists were examined in male normotensive New Zealand white rabbits and in ra
Publikováno v:
European Journal of Clinical Pharmacology. 24:315-321
The effects of the calcium entry blocker nifedipine on blood pressure (BP) and the pressor and aldosterone responses to graded infusions of angiotensin II were studied in normal subjects using 3 protocols. Study 1 was a randomised double-blind placeb
Publikováno v:
Clinical and Experimental Hypertension. Part A: Theory and Practice. 4:1409-1418
In the treatment of severe hypertension the choice of vasodilator is limited by side-effects, of which the lupus erythematosus syndrome induced by hydralazine is potentially the most serious, particularly in patients with the slow acetylator phenotyp